Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Is Bristol Myers Squibb Stock a Buy?
08:15am, Thursday, 28'th Mar 2024
Bristol Myers is already facing a major patent cliff, but there are more on the horizon. The company is developing and launching important new medicines to replace older ones.
Bristol Myers Squibb (BMY) Rises Higher Than Market: Key Facts
06:56pm, Wednesday, 27'th Mar 2024
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $53.25, indicating a +1.33% shift from the previous trading day.
The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio
01:57pm, Wednesday, 27'th Mar 2024
With the market trading near all-time highs, undervalued healthcare stocks offer a compelling opportunity. Fundamentally, the sector could benefit from a rotation in the innovation ecosystem.
2 More Potential Biotech Buyout Targets
01:07pm, Monday, 25'th Mar 2024
M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related produ
Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors
06:56pm, Thursday, 21'st Mar 2024
In the latest trading session, Bristol Myers Squibb (BMY) closed at $51.59, marking a -0.56% move from the previous day.
Bristol Myers (BMY) Gets EC Nod for Abecma's Label Expansion
08:56am, Thursday, 21'st Mar 2024
Bristol Myers (BMY) wins European Commission's approval for the label expansion of its CAR T cell immunotherapy Abecma in earlier lines for triple-class exposed relapsed and refractory multiple myelom
Bristol Myers liver cancer treatment meets main goal of late-stage study
07:07am, Wednesday, 20'th Mar 2024
Bristol Myers Squibb said on Wednesday a combination of its drugs, Opdivo and Yervoy, met the main goal of a late-stage study evaluating it as a first-line treatment for a type of liver cancer.
Bristol Myers' (BMY) Abecma Gets ODAC Votes for Label Expansion
10:36am, Monday, 18'th Mar 2024
Bristol Myers' (BMY) Abecma gets eight out of 11 votes from the FDA's ODAC for patients with triple-class exposed relapsed or refractory multiple myeloma in earlier lines of therapy.
US FDA panel votes in favor of expanded use of Bristol Myers' CAR-T therapy
05:06pm, Friday, 15'th Mar 2024
Advisers to the U.S. Food and Drug Administration on Friday voted in favor of allowing the use of Bristol Myers Squibb's cell therapy as an earlier treatment for a type of blood cancer.
Bristol Myers (BMY) Gets FDA Nod for Breyanzi's Label Expansion
10:16am, Friday, 15'th Mar 2024
Bristol Myers (BMY) obtains FDA approval for the label expansion of CAR T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or
US FDA expands use of Bristol Myers' cancer therapy
09:48pm, Thursday, 14'th Mar 2024
The U.S. Food and Drug Administration on Thursday expanded the use of Bristol Myers Squibb's cell therapy, Breyanzi, for a type of slow-growing blood cancer, marking the second approval for the treatm
Bristol Myers Squibb (BMY) Sees a More Significant Dip Than Broader Market: Some Facts to Know
06:56pm, Thursday, 14'th Mar 2024
Bristol Myers Squibb (BMY) concluded the recent trading session at $52.49, signifying a -0.3% move from its prior day's close.
Get Paid To Wait: 13 Potential Dividend Opportunities
12:15pm, Thursday, 14'th Mar 2024
The Efficient Market Hypothesis states that the stock market is efficiently priced, and therefore it is impossible to consistently generate alpha.
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
10:06am, Thursday, 14'th Mar 2024
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Bristol-Myers Squibb Company (BMY) Management Presents at Leerink Partners Global Biopharma Conference 2024 Conference (Transcript)
01:07pm, Wednesday, 13'th Mar 2024
Bristol-Myers Squibb Company (BMY) Management Presents at Leerink Partners Global Biopharma Conference 2024 Conference (Transcript)
